We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Molecular Markers of Prognosis in Colorectal Cancer Patients

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00220142
First Posted: September 22, 2005
Last Update Posted: May 31, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Royal Marsden NHS Foundation Trust
September 20, 2005
September 22, 2005
May 31, 2013
November 2003
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00220142 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Molecular Markers of Prognosis in Colorectal Cancer Patients
Molecular Markers of Prognosis in Colorectal Cancer Patients
To correlate the molecular profile of a series of defined CRCs with prognosis and toxicity.
Not Provided
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
The GI unit Royal Marsden Hospital NHS trust (RMHNHST) has co-ordinated and published results from a large multicentre randomised clinical trial of patients with locally advanced CRC (Saini et al. 2003). A total of 716 patients Dukes' B and C CRC operated with curative intent were randomised to receive either bolus or infusional 5FU regimes. Patients treated at the RMHNHST made up the majority of the total sample cohort (n=550). Analysis of results after a median of 19.8 months follow-up showed that infused 5-FU given over 12 weeks resulted in similar survival to bolus 5-FU and FA over a six-month period (log rank p=0.764). There was, however, significantly less toxicity associated with the infusional regime.
Colorectal Cancer
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
103
Not Provided
Not Provided

Inclusion Criteria:

  • All patients participating in the RMHNHST study of infusional versus bolus 5FU (Saini et al. 2003).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00220142
2348
No
Not Provided
Not Provided
Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
Not Provided
Principal Investigator: David Cunningham Royal Marsden NHS Foundation Trust
Royal Marsden NHS Foundation Trust
May 2013